logo
 
WEDNESDAY, MARCH 25 Newsletter 2 - Newsletter 3 - Newsletter 4
SYMPOSIUM NEWS
 

Weather


 

29th ISICEM OPEN!

The 29th ISICEM was opened by Prof Jean-Louis Vincent, Head of the Dept of Intensive Care at Erasme Hospital in Brussels and the meeting’s chairman. After a brief word of welcome to the packed auditorium, Prof Vincent focused on the difficulties in conducting clinical trials in critically ill patients. He presented results of a recent review showing that of 72 multicenter randomized controlled studies conducted in the ICU, only 10 showed a positive effect of the intervention on mortality. He proposed that although randomized controlled trials may be at the top of the pyramid of evidence in terms of quality they do not provide all the answers. Other study types must also be considered. Observational studies, for example, when conducted with adequate statistical analysis can provide important data with more generalizability and are cheaper to conduct. In closing, Prof Vincent encouraged us to carefully listen to all the results that will be presented during the meeting from whatever study type.

Each year prior to the ISICEM, a closed Round Table meeting is held on a topic of current importance and interest. This year’s subject was ICU-acquired weakness and, led by the chairmen, Dr Richard Griffiths and Dr Jesse Hall, an international panel of 21 experts spent 2 1/2 days debating and brain-storming all aspects of this condition which can have important implications for morbidity and long-term outcomes. The chairmen briefly summarized the discussions, stressing our general lack of knowledge in this field, the importance of prevention by early mobilization and reduced sedation, and of greater awareness, recognition and diagnosis.

Finally, Dr Finfer presented some results from the much awaited Australasian/Canadian NICE-SUGAR study. Results from the single-center study by Dr Greet Van den Berghe and colleagues in 2001 had suggested that tight control of blood sugar concentrations could improve survival rates but later multicenter studies couldn’t replicate these results and raised concerns about the harmful effects of increased hypoglycemic episodes. In NICE-SUGAR, 6104 patients were randomized to management targeting a blood glucose of 4.5-6 mmol/l or of <10 mmol/l. There were no differences between groups in 28-day mortality rates, but at 90-days the mortality rate was significantly higher in the intensive treatment group. Rates of hypoglycemia were also higher. Dr Finfer concluded that in ICU patients treated predominantly with enteral nutrition, targeting normoglycemia cannot be recommended.

Pre-symposium courses

Mechanical ventilation: With sessions covering lung mechanics in
health and disease, basic ventilator design, patient-ventilator interactions, non-invasive ventilation, and potential strategies for the future of mechanical ventilation, this 2-day course, run by three experts in the field, Dr Neil MacIntyre, Dr Arthur Slutsky and Dr Marco Ranieri, provided participants with a real opportunity to update their understanding of the various technical and physiologic aspects of mechanical ventilation. All the participants particularly enjoyed the chance to put some of the theory into practice during the hands-on workshops when they could themselves set up and explore different ventilator devices.
 

Echocardiography:
Course directors, Dr Anthony McLean, Dr Michel Slama, Dr Antoine Vieillard-Baron and Dr Jan Poelaert, gave participants the opportunity to develop (for the beginners) and improve (for the advanced) their skills in echocardiography, a technique which is becoming increasingly important in the diagnosis and monitoring of various cardiac-related disease processes in the ICU. Hands-on sessions offered participants the chance to practice some of their new-found skills and familiarize themselves with some of the measurement techniques, and case-presentations helped bring the theory to life demonstrating the real clinical application and usefulness of critical care echocardiography.
 

Abdominal compartment syndrome:
Despite potential implications for many areas of ICU patient care, the importance of intra-abdominal hypertension is still under-appreciated. This comprehensive course, lead by two leaders in the field, Dr Manu Malbrain and Dr Jan de Waele,  provided a full review of the basic physiology, epidemiology, measurement and monitoring, and management of intra-abdominal hypertension and abdominal compartment syndrome. Skills sessions provided a chance to practice measuring intra-abdominal pressure and to apply temporary abdominal closure.


ICU follow-up clinics?


Increasingly we are being encouraged to think outside the ICU box and concentrate on what effect critical illness and ICU admission can have on longer term outcomes. ICU survivors are known to have higher mortality rates than the general population for up to 17 years after discharge and worse health-related quality of life. Dr Brian Cuthbertson presented the results of a study in the UK in which severely ill ICU patients were randomized to standard follow-up or a nurse-led program of extended follow-up with clinic visits at 3 and 9 months and including case-review, psychological assessment and referral where necessary, physical rehabilitation, occupational therapy, drug review. At 12 months, there were no differences between groups in health-related quality of life, depression scores, patient satisfaction, back to work rates, or mortality.


Invitation to the Baxter satellite symposium (Lunch will be served)

Keeping the right balance: Challenging current perceptions volume replacement

It gives us great pleasure to invite you to join us for this interesting scientific satellite symposium taking place today at Hall 11, Hippocrates room at 12.30h. We will be joined by the experts in the field below for a stimulating discussion about how to optimise volume replacement therapy, and learn how total balanced volume replacement therapy can deliver improved clinical outcomes and high-quality patient care.

  • Total balanced volume replacement - Joachim Boldt (Klinikum der Stadt Ludwigshafen, Germany)
  • New guidelines on fluid therapy: the UK perspective- Dileep Lobo (Queens Medical Center, Nottingham, UK)
  • Back to basics: the physiological impact of volume replacement therapy - Can Ince (Academic Medical Center, Amsterdam, Netherlands)

We look forward to seeing you. (138 words)

 

 


 
Exhibition area open!



Yesterday evening, the Scientific Exhibition was officially opened during a cocktail reception. The exhibition area covers some 22,300 m2 with 222 stalls. The latest in medical and scientific equipment, pharmaceutical products, books, and services related to intensive care and emergency medicine are displayed by leading companies in various aspects all fields of intensive medicine. Participants are free to browse at their leisure to discover the very latest advances in diagnostics, monitoring and therapeutics.

Posters of 518 abstracts are also on display in the Exhibition Area. The winners of this Year’s best posters will be announced on Thursday at 10.40 in the Erasmus Room – watch this space!

 

Should we SDD?

Selective digestive decontamination (SDD) has been promoted as a means of reducing the incidence of nosocomial infections, but does it actually work? In an interesting pro-con debate, Dr Zandstra from Amsterdam concisely presented his viewpoint that SDD can reduce nosocomial infections and improve survival rates without increasing antimicrobial resistance, with minimal adverse effects, and at low or neutral costs. Dr Wiener-Kronish, however, suggested that, although SDD may work in the Netherlands, where resistance rates are low and the structure of care is somewhat different, she did not believe it would be effective in her ICU in the USA. She also raised the point that selective oropharyngeal decontamination alone may be sufficient and this could be achieved by methods other than antibiotics, such as chlorhexidne mouth washes or early tracheostomy which would limit any possible effects on resistance.

In rebuttal, Dr Zandstra claimed that chlorhexidine was not efficacious at reducing Gram-negative infections, that early tracheostomy could actually increase infections, and that the Netherlands was not in fact the no-resistance paradise it was widely reported to be so that results could be relevant in other units. At the end of the debate, the two speakers clearly remained firmly on their respective pro and con fences!

Welcome to the Baxter stand

We would be pleased to welcome you at the Baxter exhibition booth in Hall 7
(booth no. 07.029-07.032).

  • Join us for a coffee and a freshly baked Belgian waffle.
  • Take part in our interactive quiz about nutrition facts.
  • Learn about Baxter’s volume replacement therapy.
  • Do you know your current MRSA (Methicillin resistant Staphylococcus aureus) status?

Get your free MRSA status check at the Baxter booth.
It’s an easy 2 minutes nasal swab. You will get an accurate result from DNA based testing. You will be assigned a number to make the test completely anonymous. Give enhanced patient care by combining good aseptic technique and Baxter’s novel technology.

Looking forward to seeing you at the Baxter booth.

 

 

 

Burning Questions for ICU Physicians: Treatment of Invasive Fungal Infections
TODAY, 12.30pm. Harvey Room. Lunch provided.

Astellas Pharma Europe Ltd. sponsors interactive discussion with an expert panel:
David Denning
Oliver Cornely
Olivier Lortholary

Clinical challenges:

  • Issues with fluconazole prophylaxis
  • Candida epidemiology
  • Echinocandins in ICU
  • Catheter policy

22nd Annual Congress of the European Society of Intensive Care Medicine, Vienna, Austria, 11-14 October 2009

Online registrations open on 6 April 2009

 


Update on new therapeutic options for managing multidrug-resistant Gram-positive pneumonia

The opening day at the 29th ISICEM featured an interesting and thought provoking satellite symposium sponsored by Astellas Pharma Europe Ltd. This symposium provided an opportunity for ICU physicians to explore the clinical challenges involved in the selection of appropriate and timely antibacterial therapy when managing critically ill patients with serious multidrug-resistant Gram-positive bacterial infections.

The expert faculty, Jean Chastre, Matteo Bassetti and Jean-Yves Fagon, provided an in-depth review of the issues posed by the emergence and spread of methicillin-resistant Staphylococcus aureus, and strains with reduced susceptibility to currently available agents. This included risk factors for acquisition of a multidrug-resistant pathogen and the need for new therapeutic options. The faculty discussed future therapeutic options for serious hospital-acquired infections, including pneumonia, and their implications for treatment strategies in the future.

Slide resource available at exhibition stand

If you missed the opportunity to attend this symposium then please visit the Astellas Pharma Europe Ltd. exhibition stand which features educational materials relating to the treatment of serious bacterial and fungal infections in the ICU. These include a slide resource which is available to download onto USB drives at the exhibition stand.


 

 
 
This is just a small selection of the many sessions held yesterday.
For our full program visit www.intensive.org